Physician profile
John P Wornock
NPI 1386614097
$1,255.74
in general payments reported to CMS, 2019-2025
19 companies · $20.85 in 2025
The $20.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.35 · 2020: $614 · 2021: $57.53 · 2022: $90.73 · 2023: $270 · 2024: $116 · 2025: $20.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $644.97 | 2019-2023 | Bexsero |
| Abbott Laboratories | $150.82 | 2023-2024 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $65.71 | 2021-2023 | Jornay Pm |
| Tris Pharma INC | $60.60 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $50.52 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $40.99 | 2023 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $37.26 | 2022-2023 | |
| Pfizer INC. | $32.64 | 2019-2025 | |
| Seqirus USA INC | $18.51 | 2024 | Fluad, Flucelvax |
| Paratek Pharmaceuticals, INC. | $18.33 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.10 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.72 | 2019 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.53 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.01 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.95 | 2020 | |
| Lilly USA, LLC | $12.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wornock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.